Project Grant R01CA292851
Award Date 7/5/24
Completion Date 6/30/29
Dollars Obligated $1.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Buffalo, NY 14203, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the Dana-Farber Cancer Institute (DFCI) to investigate targeting the CDK4/6 pathway as a potential therapeutic strategy for translocation renal cell carcinoma (TRCC), an aggressive form of kidney cancer. The $267,298 award, effective from February 1, 2025 to January 31, 2027, will support in vitro and in vivo studies to test the sensitivity of TRCC cells to CDK4/6 inhibition,...
- The federal Project Grant award for $172,193 was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) to the Dana-Farber Cancer Institute, Inc. (DFCI) located in Massachusetts. The goal of this 5-year project is to characterize subtype-specific gene regulatory elements in translocation renal cell carcinoma (TRCC), a rare and aggressive form of kidney cancer, by identifying differentially active transcription factors, determining their metabolic...
- The $178,999.00 Project Grant was awarded on May 15, 2025 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System. The grant is focused on "Targeting TFE3 Fusion Proteins Using PROTAC in Translocation Renal Cell Carcinoma (TRCC)," supporting advanced biomedical research to transform healthcare for military service members, veterans, and the public. Through...
- This $483,395 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research by The Institute For Cancer Research (ICR) to investigate targeting the P300/CBP proteins as a novel therapeutic approach for renal cell carcinoma (RCC). The key objectives are to examine the therapeutic potential of inhibiting P300/CBP in clear cell RCC, and establish the association between P300/CBP expression and disease progression, drug-resistance, and...
- This $396,061 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to assess the efficacy of a novel class of hypoxia-inducible factor (HIF) inhibitors as a potential treatment for renal cell carcinoma (RCC). The principal investigator has developed boron-based HIF inhibitors derived from the natural compound honokiol, which have demonstrated promising anti-angiogenic properties in vitro. This 2-year project aims to (1) determine...
- The Department of the Army Medical Command awarded a $694,200 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to support research developing a novel therapeutic target in XP11.2 translocation renal cell carcinoma. The grant was awarded on July 1, 2022 under the Military Medical Research and Development program (CFDA 12.420), with a completion date of June 30, 2025. Through this funding, Dfci will conduct research to investigate medical solutions for renal cell...
- The federal Project Grant award for "TARGETING P2X7 RECEPTOR IN RENAL CELL CARCINOMA", totaling $1,269,000.00, was awarded to The Institute For Cancer Research, a non-profit subsidiary of Temple University, by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports biomedical research focused on developing new treatments for kidney cancer, a key health concern for military service members and veterans. The Institute For...
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $999,096.00 to The University of Texas Southwestern Medical Center to conduct research on "Targeting DNA Damage Response to Treat Clear Cell Renal Cell Carcinoma." The award period runs from July 1, 2024 to June 30, 2028. The research aims to develop new treatments for clear cell renal cell carcinoma, a type of kidney cancer, by investigating...
- This R03 project grant, awarded by the National Center for Advancing Translational Sciences (NCATS) under CFDA Program 93.350, aims to comprehensively identify metabolic enzymes that control the generation of TCF1+ progenitor CD8+ T cells, which are critical for durable anti-tumor immune responses. The $169,500 award, spanning from September 1, 2024 to August 31, 2026, will fund two key research objectives: Identifying metabolic enzymes whose loss alters T cell differentiation and the TCF1+...
- This federal Project Grant award of $400,000 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the advancement of next-generation CAR-T cell therapies for renal cell carcinoma (RCC). The award recipient, Cellinfinity Bio Inc., is developing novel CAR-T cell modifications, including a PRDM1 exon 3 knockout and a CTLA-4 cytoplasmic tail fusion, to enhance CAR-T cell efficacy against RCC tumors. The project aims to evaluate the combination of these...